Loading...
XKRX
206650
Market cap307mUSD
Dec 05, Last price  
12,430.00KRW
1D
0.16%
1Q
-9.07%
IPO
191.44%
Name

EuBiologics Co Ltd

Chart & Performance

D1W1MN
XKRX:206650 chart
P/E
23.85
P/S
4.72
EPS
521.11
Div Yield, %
Shrs. gr., 5y
6.01%
Rev. gr., 5y
23.76%
Revenues
96.04b
+38.45%
1,602,679,0914,844,900,24011,567,747,40324,891,999,06233,072,579,69928,489,676,01239,384,938,14755,466,694,23669,365,660,61096,035,298,000
Net income
18.99b
P
-2,828,023,339-6,702,365,737-4,715,309,4353,780,519,903-881,624,055-60,134,488,690-27,574,028,750-1,098,855,365-13,878,968,42018,991,722,000
CFO
43.21b
+63.36%
-3,394,978,841-3,694,345,897-2,640,240,9792,936,794,20412,878,282,894-913,537,169-7,601,892,5706,440,151,98526,451,775,86043,211,898,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

EuBiologics Co., Ltd., a biopharmaceutical company, develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine. The company also provides customized services for mammalian cell and microbial cell derived biopharmaceuticals in accordance with the clients' project stages, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. It specializes in manufacturing a range of mammalian cell and microbial cell derived biopharmaceuticals, including recombinant biological products and antibody therapeutics. In addition, the company offers process, formulation, and analytical method development, as well as licensing consulting services; and contract testing services that include lot release, stability, raw material, and method validation testing services. The company was founded in 2010 and is based in Seoul, South Korea.
IPO date
Jan 24, 2017
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT